A WORLD WITHOUT CANCER: WE’RE BRINGING IT CLOSER EVERY DAY

HOW DOES OUR hhc MISSION INSPIRE ONCOLOGY BREAKTHROUGHS? HERE’S A REAL-WORLD EXAMPLE

When we first set out to develop a new anti-cancer agent, we didn’t sacrifice quality for speed. We concentrated on diseases with poor prognoses and few treatment options, regardless of the size of the patient populations. We prioritized how the compound would bind to certain targets implicated in the pathogenesis of the cancer.

Our determination to address patients' unmet medical needs drove us to synthesize a chemical process with millions of steps. Ultimately, it led us to develop a targeted agent.

We're now investigating that agent with Merck (known as MSD outside the United States and Canada) in combination with their anti-PD-1 therapy in different kinds of cancer in the hopes of reaching more patients in need. In fact, Eisai and Merck received three Breakthrough Therapy designations and one approval from the FDA.

We're evaluating the combination in 13 tumor types across 18 clinical trials:

• Endometrial carcinoma
• Hepatocellular carcinoma
• Renal cell carcinoma
• Non-small cell lung cancer
• Head and neck squamous cell carcinoma
• Melanoma
• Urothelial carcinoma

And a second basket trial targeting six other cancer types is also under way, which means that Eisai and Merck may impact the lives of even more patients.